White Paper

Transforming Pharmacovigilance with AI, RWE & Responsible Innovation

From Automation to Accountable AI In my previous article - Future-fit Pharmacovigilance, I examined why inspection findings and FDA 483 observations are increasingly linked to process gaps, inadequate oversight, and weak digital governance in pharmacovigilance.